Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 51

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 51
---
 the CEO, President or CFO of the Company, dated as of the Commencement
Date, to the foregoing effect in the form attached hereto as Exhibit A;

(f) The
Board of Directors, or a committee thereof, shall have adopted resolutions approving the transactions contemplated hereby, which resolutions
shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date;

(g) As
of the Commencement Date, the Company shall have allotted (i) solely for the purpose of effecting purchases of Purchase Shares hereunder,
up to 350,000,000,000 Ordinary Shares, which represents 35,000,000 Depositary Shares sold at the Floor Price per Depositary Share, and
(ii) solely for the purpose of effecting the issuance of Commitment Shares hereunder, if any, up to 8,750,000,000 Ordinary Shares, which
represents 875,000 Depositary Shares issued at the Floor Price per Depositary Share;

(h) .

(i) The
Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in England and
Wales issued by the Companies House as of a date within ten (10) Business Days of the Commencement Date;

(j) The
Company shall have delivered to the Investor a certified copy of the Articles of Association as certified by the Companies House within
ten (10) Business Days of the Commencement Date;

(k) The
Company shall have delivered to the Investor an officer’s certificate executed by the Chief Financial Officer of the Company, dated
as of the Commencement Date, in the form attached hereto as Exhibit B;

(l) The
Registration Statement covering the resale of up to 35,000,000 Purchase Shares and up to 875,000 Commitment Shares shall have been declared
effective under the Securities Act by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened
by the SEC. The Company shall have prepared and filed with the SEC, not later than one (1) Business Day after the effective date of the
Registration Statement, a final and complete prospectus (the preliminary form of which shall be included in the Registration Statement)
and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be current and available for the resale
by the Investor of all of the Securities covered thereby. The Current Report shall have been filed with the SEC as required pursuant to